Real‐world experience of using dupilumab and JAK inhibitors to manage pruritus in epidermolysis bullosa pruriginosa-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real‐world experience of using dupilumab and JAK inhibitors to manage pruritus in epidermolysis bullosa pruriginosa

Published:2024-08-19 Issue: Volume: Page:
ISSN:2690-442X
Container-title:Skin Health and Disease
language:en
Short-container-title:Skin Health and Disease

Author:

Hou Ping‐Chen¹^ORCID,Aala Wilson²^ORCID,Tu Wei‐Ting¹^ORCID,McGrath John A.¹³^ORCID,Hsu Chao‐Kai¹²⁴^ORCID

Affiliation:

1. Department of Dermatology National Cheng Kung University Hospital College of Medicine National Cheng Kung University Tainan Taiwan

2. Institute of Clinical Medicine College of Medicine National Cheng Kung University Tainan Taiwan

3. St John's Institute of Dermatology School of Basic and Medical Biosciences King's College London London UK

4. International Center for Wound Repair and Regeneration National Cheng Kung University Tainan Taiwan

Funder

National Science and Technology Council

National Cheng Kung University Hospital

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ski2.445

Reference10 articles.

1. Dystrophic epidermolysis bullosa pruriginosa: a new case series of a rare phenotype unveils skewed Th2 immunity

2. Treatment of epidermolysis bullosa pruriginosa‐associated pruritus with dupilumab

3. Epidermolysis Bullosa Pruriginosa Treated With Baricitinib

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP